Haem oxygenase-1 (HO-1) is induced by thiazolidinediones including rosiglitazone and exerts anti-inflammatory effects in various models. However, the molecular mechanisms underlying rosiglitazone-induced HO-1 expression remain largely unknown in human pulmonary alveolar epithelial cells (HPAEpiCs).
Introduction
LPS triggers acute lung inflammation during bacterial infections, through up-regulation of adhesion molecules, such as intercellular adhesion molecule (ICAM-1) and VCAM-1, leading to the recruitment of polymorphonuclear cells to inflammatory tissues and airway fluid (Liou et al., 2016; Woodfin et al., 2016) . The up-regulation of adhesion molecules is involved in pathological changes in the lung. Thus, either ICAM-1 or VCAM-1 could serve as an inflammatory marker and have been used to evaluate the anti-inflammatory effects of haem oxygenase 1 (HO-1) in our studies. We also confirmed that LPS-induced ICAM-1 or VCAM-1 expression and monocytes (THP-1) adhesion might be used to evaluate the progression of lung inflammation (Cho et al., 2016) . Therefore, pursuing an effective medicine to target these critical components is important in the management of pulmonary inflammatory diseases.
Thiazolidinediones (TZD) have been shown to activate PPARγ and have potential value in treatment of animal models of inflammatory diseases. Their anti-inflammatory effects result from up-regulation of HO-1 which suppresses pulmonary artery cell proliferation and vascular remodelling (Kronke et al., 2007; Li et al., 2010) and decreases LPS-induced lung inflammatory responses (Liu et al., 2005; Wang et al., 2014) . We recently also confirmed that suppression of LPS-mediated inflammation (VCAM-1 expression and cell adhesion) by HO-1, induced by rosiglitazone, was mediated through PKCα/AMPKα/p38 MAPKα/SIRT1-dependent deacetylation of Ac-PGC1α and fragmentation of NCoR/PPARγ activation in human pulmonary alveolar epithelial cells (HPAEpiCs) (Cho et al., 2018) . These studies demonstrate that PPARγ agonists could exert anti-inflammatory effects through a PPARγ-dependent HO-1 up-regulation.
HO-1 induced by various stimuli and oxidative stresses protects against inflammatory responses (Rushworth et al., 2005; Huang et al., 2014) . The ROS-dependent activation of signalling kinases (Polvani et al., 2012) by PPAR agonists could regulate the expression of various genes (Gardner et al., 2005) . PPARγ ligands could also inhibit airway inflammation and hyperresponsiveness via a PPARγ-independent mechanism in mouse models challenged with allergen (Donovan et al., 2012) . In addition, the NADPH oxidase (NOX)ROS system could induce HO-1 expression through different signalling components. Indeed, c-Src is an upstream component of proline-rich tyrosine kinase 2 (Pyk2) phosphorylation stimulated by TZDs (Peng et al., 2003; Dewar et al., 2007) , which is regulated by ROS (Ke et al., 2014) , leading to HO-1 expression in various cell types (Han et al., 2009; Chi et al., 2015; Yang et al., 2015) . Activated Akt triggers nuclear factor erythroid-2-related factor (Nrf2)/ HO-1 expression which could protect against cellular injury and promote cell survival (Deng et al., 2013; Xu et al., 2015b) . However, whether rosiglitazone-induced HO-1 expression mediated through NOX/ROS, c-Src, Pyk2, Akt and Nrf2 was still unknown in HPAEpiCs.
Nrf2 is involved in the HO-1 gene transcription through binding to antioxidant response elements (AREs) in the promoter region in response to ROS (Alam and Cook, 2007; Loboda et al., 2016) . On exposure to ROS, Nrf2 dissociates from kelch like ECH associated protein 1 (Keap1) and translocates into the nucleus, wherein Nrf2 oligomerizes with the protein Maf binding to the ARE sites of target genes and leading to gene transcription (Itoh et al., 1999; Baird et al., 2013; Foresti et al., 2013) . However, the detailed mechanisms of intracellular signalling pathways involved in the rosiglitazoneinduced HO-1 expression in HPAEpiCs were not completely defined. Here, we have shown that the expression of HO-1 induced by rosiglitazone is mediated through not only PPARγ-dependent but also through a separate NOX/ROS/c-Src/ Pyk2/Akt-dependent Nrf2 activation pathway and protects against the LPS-mediated inflammatory responses.
Methods

Animal care and experimental procedures
All animal care and experimental procedures complied with the guidelines of the Animal Care Committee of Chang Gung University and NIH Guides for the Care and Use of Laboratory Animals. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Male ICR mice aged 6-8 weeks were purchased from the National Laboratory Animal Centre (Taipei, Taiwan). Mice were assigned randomly into three groups: sham [0.1 mL of DMSO-PBS (1:100) with 0.1% (W/V) BSA treated mice], LPS (LPS-treated mice) and Rosi + LPS (rosiglitazone plus LPS mice); five mice in each group/cage and kept in standard individually ventilated cages in an animal facility under standardized conditions (12 h light/dark cycle, 21-24°C, humidity of 50-60%) with food and water ad libitum. Mice treated with rosiglitazone (i.p.; 0.1 mg·kg À1 ) and 1 h later were anaesthetized with pentothal (i.p.; 50 mg·kg À1 ). Mice were placed individually on a board in a near vertical position and the tongues withdrawn with lined forceps. LPS (3 mg·kg À1 ; 45 μL in 30g mouse) was placed posteriorly in the throat and aspirated into lungs for 16 h to provide a model of lung inflammation (Hsu et al., 2014) . At the end of the experimental period, mice were killed by an overdose of pentothal (i.p.; 100 mg·kg
À1
) for collection of lung tissues. These tissues were extracted for protein (right superior lobe + post caval lobe) and mRNA (right middle lobe + right inferior lobe) for ICAM-1, HO-1 or β-actin. Data collection and evaluation of all in vivo and in vitro experiments were performed without knowledge of the treatment of the group.
Immunohistochemical (IHC) staining
To examine the cellular expression and location of the ICAM-1 or HO-1 protein, immunohistochemical (IHC) staining was performed on the sections of the lung tissues (left lung), which were deparaffinized, rehydrated and washed with TTBS (composition; 50 mM Tris-HCl, 150 mM NaCl, 0.05% (w/v) Tween 20, pH7.4). Non-specific binding was blocked by preincubation with PBS containing 5 mg·mL À1 of BSA for 1 h at room temperature. The sections were incubated with an anti-ICAM-1 or anti-HO-1 antibody (1:100 dilution) at 4°C for 16 h and then with anti-mouse or anti-rabbit HRP antibody at room temperature for 1 h. Bound antibodies were detected by incubation in 0.5 mg·mL À1 of 3,3-diaminobenzidine/0.01% (v/v) hydrogen peroxide (H 2 O 2 ) in 0.1 M Tris-HCl buffer, as chromogen (Vector Lab, Burlingame, CA, USA).
Cell culture
HPAEpiCs were purchased from the ScienCell Research Laboratories (San Diego, CA, USA). Cells were cultured in DMEM/F12 medium containing 10% (v/v) FBS and antibiotics (100 U·mL À1 penicillin G, 100 μg·mL À1 gentamicin and 250 ng·mL À1 fungizone) at 37°C in a humidified 5% CO 2 . Experiments were performed with cells from passages 4 to 7. The growth medium was changed after 24 h and then every 3 days. The viability of HPAEpiCs after treatment with 1% (v/v) DMSO or the pharmacological inhibitors alone was determined by a cell counting Kit-8 assay, which showed no significant differences (data not shown).
Protein preparation and Western blot analysis
Cells were incubated with or without different concentrations of rosiglitazone at 37°C for the indicated time periods. When inhibitors used, they were added 1 h prior to the application of rosiglitazone. The collected cells were lysed with a lysis buffer. The mixed samples (15 μL) were subjected to 10% SDS-PAGE and transferred to nitrocellulose membrane. Membranes were washed with TTBS four times for 5 min each, incubated with anti-rabbit or anti-mouse HRP antibody (1:2000 dilution) for 1 h. The immunoreactive bands were detected by ECL reagents and captured by a UVP BioSpectrum 500 Imaging System (Upland, CA, USA). The values of Western blot were quantified by UN-SCAN-IT gel version 6.1 (Utah, USA) and normalized to GAPDH or total protein for five individual experiments. Changes after LPS are expressed as fold change, relative to the mean basal value.
Real-time PCR analysis
Total RNA was extracted from HPAEpiC using TRIzol reagent. 
Transient transfection with siRNAs in HPAEpiCs
Human siRNAs of scrambled, SMARTpool RNA duplexes corresponding to p47 Keap1 (SASI_Hs01_00080908) and Scrambled control siRNA were from Sigma-Aldrich (St. Louis, MO, USA). Briefly, siRNA (100 nM) was formulated with Lipofectamine 2000 transfection reagent according to the manufacturer's instruction.
NADPH oxidase activity assay
After exposure to 30 μM rosiglitazone for the indicated time intervals, cells were gently scraped and centrifuged at 400× g for 10 min at 4°C. The cell pellet was resuspended with 35 μL of ice-cold PBS, and the cell suspension was kept on ice. To a final 200 μL volume of pre-warmed (37°C) PBS containing either NADPH (1 μM) or lucigenin (20 μM), 5 μL of cell suspension (2 × 10 4 cells) was added to initiate the reaction followed by immediate measurement of chemiluminescence in a luminometer (Synergy H1 Hybird Reader, BioTek, Winooski, VT, USA).
Measurement of intracellular ROS accumulation
Cells were cultured in DMEM/F-12 for 24 h and then treated with rosiglitazone. When inhibitors were used, they were added 1 h prior to the application of rosiglitazone. After washing twice with warm PBS, the cells were stained with 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (H 2 DCFDA) (10 μM) or DHE (5 μM) for 30 or 10 min. After staining, the cells were recovered with DMEM/F-12 containing 10% (v/v) FBS for 30 min in H 2 DCFDA group. For ELISA assay, the fluorescence for DCF and DHE staining was detected at 495/529 and 518/605 nm using a fluorescence microplate reader (Synergy
H1
Hybird Reader, BioTek) and FACSCalibur equipped with CellQuest software (BD Biosciences, San Jose, CA, USA). For immunofluorescence staining, the stained cells were washed three times with cold-PBS and then the fluorescence for DCF and DHE staining was detected at 495/529 and 518/605 nm, respectively, using a fluorescence microscope (Axiovert 200M, Zeiss).
Transfection and promoter luciferase assay ARE-luc reporter construct plasmids were transiently transfected at a concentration of 0.8 μg·mL Àl , and the control pGal encoding for β-galactosidase presented at 0.2 μg·mL À1 to normalize the transfection efficiency. ARE-luc luciferase activities were determined by using a luciferase assay system (Abcam, Cambridge, UK) according to the manufacturer's instructions. Detected firefly luciferase activities were standardized with β-galactosidase activity.
Isolation of subcellular fractions
The cytosolic and nuclear fractions were isolated, as described previously (Cho et al., 2016) . The cells were harvested, sonicated for 10 s at output 1.5 with a sonicator (Misonix, Farmingdale, NY, USA) and centrifuged at 5000× g at 4°C for 15 min. The pellet was collected as the nuclear fraction and the supernatant collected as the cytosolic fraction.
Chromatin immunoprecipitation (ChIP) assay
To detect the association of transcription factors with the human HO-1 promoter, the ChIP analysis was performed as previously described (Cho et al., 2016) . Briefly, HPAEpiCs were cross-linked with 1% (v/v) formaldehyde at 37°C for 30 min and stop this reaction with 0.125 M glycine, then washed three times with ice-cold PBS containing 1 mM PMSF, 1% (v/v) aprotinin and 1% (v/v) leupetin. Soluble chromatin was prepared using a ChIP assay kit (Upstate) according to the instructions of the manufacturer and immunoprecipitated without (control) or with an anti-Nrf2 antibody and normal goat IgG. Following washing and elution, immunoprecipitates were heated overnight at 65°C to reverse cross-linking of DNA and protein. To avoid the possibility of amplification artefacts, PCR products for all SYBR Green primer pairs were verified to produce single products by agarose electrophoresis and high resolution melt curve. The relative mRNA levels were calculated using the comparative Ct method (ΔΔ Ct ). The DNA was extracted and resuspended in H 2 O and subjected to PCR amplification with the ARE primers: ARE (327 bp)
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) . Statistical analysis was performed only when n = 5 independent samples were acquired. All data are expressed as means ± SEM, from five individual experiments (n ≥ 5). Statistical analysis was performed by using GraphPad Prizm Program 6.0 software (GraphPad, San Diego, CA). We used one-way ANOVA followed by Dunnett's post hoc test when comparing more than two groups of data and one-way ANOVA with a non-parametric Kruskal-Wallis test, followed by Dunnett's post hoc test when comparing multiple independent groups. Post tests were run only if F achieved P < 0.05 and there was no significant variance inhomogeneity. P < 0.05 was considered to show statistical significance. Error bars are omitted when they fell within the dimensions of the symbols.
Materials
Apocynin ( ) (rabbit polyclonal antibody, Cat# 9271, RRID: AB_329825) were from Cell Signaling Technology (Danvers, MA, USA). Rosiglitazone, GW590735, GW0742, ciglitazone, pioglitazone, troglitazone, GW9662 and ZnPPIX were from Cayman Chemical (Ann Arbor, MI, USA). PF431396, c-Srci II and Akt inhibitor VIII were from Merck (Merck Millipore, Billerica, MA, USA). BCECF-AM, dihydroethidium (DHE) and CM-H 2 DCFDA were from Molecular Probes (Eugene, OR, USA). N-acetyl-L-cysteine (NAC), LPS (L2630) and other chemicals were from Sigma-Aldrich. SDS-PAGE supplies were from MDBio Inc (Taipei, Taiwan).
Results
Up-regulation of HO-1 inhibits inflammatory responses in mice challenged with LPS
HO-1 has been shown to protect against the inflammatory responses induced by various insults including LPS (Liu et al., 2005; Xu et al., 2015a) . Therefore, we confirmed these results in an in vivo study. We observed that LPS markedly induced ICAM-1 expression, which was attenuated by rosiglitazone through up-regulation of HO-1, determined by IHC staining ( Figure 1A ). We also found that LPS significantly enhanced ICAM-1 mRNA and protein expression, which were attenuated by rosiglitazone via up-regulation of HO-1 ( Figure 1B,C) . These results suggested that up-regulation of HO-1 by rosiglitazone protects lung tissues against the expression of inflammatory proteins such as ICAM-1, following exposure to LPS.
PPARs stimulate expression of HO-1 protein
Activation of PPARs by agonists could inhibit the proliferation of pulmonary artery cells and reduce pulmonary vascular remodelling by HO-1 up-regulation (Kronke et al., 2007; Li et al., 2010) . To investigate whether PPARα, PPARδ or PPARγ agonists could induce HO-1 expression in HPAEpiCs, the cells were treated with the agonist of PPARα (GW590735), PPARδ (GW0742) or PPARγ (rosiglitazone) for the indicated time intervals. These agonists time-dependently induced HO-1 protein expression ( Figure 2A ). Other PPARγ agonists (ciglitazone, pioglitazone and troglitazone) over a range of concentrations (0.1 -30 μM) were used to induce HO-1 expression. At the highest concentration (30 μM), these three agonists, but not rosiglitazone, induced cell death of HPAEpiCs. We
Figure 2 therefore chose lower concentrations of ciglitazone, pioglitazone and troglitazone to induce the expression of HO-1 ( Figure 2B ). As the level of HO-1 expression by rosiglitazone (3.6 ± 0.1 fold; Figure 3A ) was greater than those after ciglitazone (2.7 ± 0.2 fold), pioglitazone (2.8 ± 0.1 fold) and troglitazone (3.0 ± 0.3 fold) over 16 h (all at 10 μM). Therefore, we chose rosiglitazone as an inducer for the following experiments in this study.
Rosiglitazone induces HO-1 expression
The mechanisms underlying rosiglitazone-induced HO-1 gene expression were dissected in HAPEpiCs. We found that rosiglitazone time-and concentration-dependently induced HO-1 protein expression ( Figure 3A ). There was a significant increase within 10 h and reaching a maximal response within 24 h. Moreover, the levels of HO-1 mRNA were also enhanced by rosiglitazone ( Figure 3B ). We also evaluated the effect of HO-1 up-regulation induced by rosiglitazone on LPS-induced ICAM-1 expression. HPAEpiCs were pretreated with 30 μM rosiglitazone for 1 h and then continuously incubated with or without 1 μM ZnPPIX (a HO-1 activity inhibitor) for 1 h, and finally treated with 20 μg·mL À1 LPS for 16 h. As shown in Figure 3C ,D the levels of HO-1 protein and mRNA were significantly increased in HPAEpiCs challenged with rosiglitazone, which accompanied with down-regulation of ICAM-1 expression induced by LPS and was reversed by treatment with ZnPPIX. In addition, treatment with ZnPPIX also blunted the reduction, induced by rosiglitazone, of the adhesion of THP-1 cells to HPAEpiCs challenged with LPS ( Figure 3E ), suggesting that HO-1 induction by rosiglitazone protects against monocyte adhesion to HPAEpiCs, challenged with LPS.
NOX-derived ROS generation is required for rosiglitazone-induced HO-1 expression HO-1 is induced by intracellular oxidative stress or imbalance between intracellular redox conditions (Loboda et al., 2016) . Activation of NOX is one of the sources of ROS which could act as second messengers leading to HO-1 expression (Seo et al., 2011) . To determine whether NOX activation and ROS generation were involved in the HO-1 expression, HPAEpiCs were pretreated with a scavenger of ROS (NAC), or inhibitors of p47 phox (APO) or NOX (DPI). As shown in Figure 4A ,B, these treatments concentration-dependently attenuated the induction of HO-1 protein ( Figure 4A ) and mRNA ( Figure 4B ) by rosiglitazone. In NOX enzymes, NOX2 has been shown to distinctly recruit p22 phox (presence) and p47 phox (regulatory subunits) to produce superoxide (O 2 •À ) in pulmonary alveolar epithelial cells (Tickner et al., 2011) . To confirm the roles of p47 phox and NOX2 in rosiglitazone-induced responses, the levels of p47 phox and NOX2 protein were knocked down by their respective siRNAs. As shown in Figure 4C , transfection with either p47 phox or NOX2 siRNA knocked down the of level p47 phox or NOX2 protein and attenuated the rosiglitazone-induced HO-1 expression in HPAEpiCs. Phosphorylation of p47 phox is a key event in NOX activation and ROS generation (Lam et al., 2010) . We found that, in HPAEpiCs, rosiglitazone-stimulated p47 phox phosphorylation, which was significantly inhibited by APO ( Figure 5A ). To further investigate whether rosiglitazone stimulates NOX activity leading to ROS generation, as shown in Figure 5B , rosiglitazone-stimulated NOX activity was blocked by pretreatment with APO (100 μM) or DPI (3 μM). Furthermore, to directly detect ROS generation in rosiglitazone-treated HPAEpiCs, the levels of intracellular H 2 O 2 and O 2 •À were determined by H 2 DCFDA and DHE respectively. Pretreatment with either APO or DPI inhibited the ROS generation induced by rosiglitazone ( Figure 5C ). These results were further supported by the data of DCF and DHE fluorescence images obtained by fluorescence microscopy ( Figure 5D ). These results suggested that rosiglitazone-induced HO-1 expression is mediated through NOX2-dependent ROS generation in HPAEpiCs.
Rosiglitazone-induced HO-1 expression is mediated via a NOX/ROS-dependent c-Src/Pyk2/Akt pathway NOX/ROS production activates downstream components such as c-Src and Pyk2 to modulate cellular functions (Peng et al., 2003; Ke et al., 2014) . In addition, rosiglitazone also attenuated endothelial progenitor cell dysfunction and increased NO production via phosphorylation of Akt, which is one of downstream signalling components of the c-Src/Pyk2 pathway (Liang et al., 2009; Deng et al., 2013) . Therefore, we investigated whether the rosiglitazone-induced HO-1 expression is mediated through activation of ROS-dependent c-Src, Pyk2 and Akt signalling components in HPAEpiCs. The inhibitors of c-Src (c-Srci II), Pyk2 (PF431396) and Akt (Akti VIII) were used for these purposes. Pretreatment with c-Srci II, PF431396 or Akti VIII significantly attenuated the rosiglitazone-induced HO-1 protein and mRNA expression in HPAEpiCs ( Figure 6A,B) . To confirm the involvement of c-Src, Pyk2 and Akt in rosiglitazone-mediated responses, as shown in Figure 6C , transfection with c-Src, Pyk2 or Akt siRNA down-regulated the level of c-Src, Pyk2 or Akt protein and then attenuated the rosiglitazone-induced HO-1 protein expression. We further determined whether phosphorylation of c-Src, Pyk2 and Akt participated in rosiglitazone-induced HO-1 expression in HPAEpiCs, by Western blot, using an antibody specific for the phosphorylated form of c-Src, Pyk2 or Akt. Rosiglitazone-stimulated the phosphorylation of c-Src which was attenuated by the siRNA for p47 phox or NOX2 and APO, DPI or c-Srci II ( Figure 7A,B) . Similarly, pretreatment with c-Srci II inhibited rosiglitazone-stimulated phosphorylation of Pyk2, but not p47 phox ( Figure 7B ), suggesting that rosiglitazone-stimulated c-Src-dependent Pyk2 phosphorylation is mediated through NOX/ROS. Moreover, pretreatment with PF431396 attenuated rosiglitazone-stimulated Pyk2 phosphorylation, but not c-Src ( Figure 7C ), implying that Pyk2 was a downstream component of NOX/ROS/c-Src cascade. Further, rosiglitazone time-dependently stimulated Akt phosphorylation which was attenuated by pretreatment with either PF431396 or Akti VIII ( Figure 7C,D) . Akti VIII failed to inhibit the Pyk2 phosphorylation. Collectively, these data suggested that rosiglitazone-induced HO-1 expression is mediated through a NOX/ROS/c-Src/Pyk2/Akt cascade in HPAEpiCs. Up-regulation of ARE promoter activity is mediated through NOX/ROS/c-Src/Pyk2/Akt/ Nrf2 cascade Nrf2, an oxidative stress sensitive transcription factor, regulates the expression of antioxidant genes including HO-1 (Alam and Cook, 2007; Loboda et al., 2016) . As addressed, Keap1 accelerates the degradation of Nrf2 via facilitating the binding of E3 ligase, and the modification of cysteine residues of Keap1 releases functional Nrf2 (Baird et al., 2013) . To assess the involvement of Keap1/Nrf2 in our model, HPAEpiCs were transfected with Nrf2 or Keap1 siRNA. As shown in Figure 8A (left panel), knockdown of Nrf2 protein expression by Nrf2 siRNA attenuated HO-1 expression induced by rosiglitazone. In contrast, transfection with Keap1 siRNA down-regulated the levels of Keap1 protein and enhanced the rosiglitazoneinduced HO-1 expression ( Figure 8A , right panel). Accumulated nuclear Nrf2 further binds to ARE on HO-1 promoter and initiates HO-1 gene expression. We found that rosiglitazone enhanced the recruitment of Nrf2 to the proximal ARE binding site on the HO-1 promoter ( Figure 8C ). The subcellular fractions and real-time PCR analyses further confirmed that pretreatment with APO, DPI, Srci II, PF431396 or Akti VIII significantly attenuated the rosiglitazone-stimulated Nrf2 phosphorylation and translocation into the nucleus and its association with the ARE binding site on the HO-1 promoter ( Figure 8B,D) . Further, to investigate whether rosiglitazone stimulated transcriptional activation of ARE, HPAEpiCs were co-transfected with an ARE luciferase reporter construct (ARE-Luc) and an internal control (pGal-Luc) and then stimulated with rosiglitazone. Rosiglitazone significantly stimulated ARE-Luc reporter activity which was attenuated by pretreatment with the respective inhibitors of NOX, c-Src, Pyk2 and Akt ( Figure 8D ). These results suggested that rosiglitazone-induced HO-1 expression is mediated through a NOX/ROS/c-Src/Pyk2/Akt pathway which then activates the Nrf2-ARE axis in HPAEpiCs.
Involvement of PPARγ in rosiglitazone-induced HO-1 expression
PPARγ is known to contribute to several cellular functions in different cell types. However, PPARγ ligands may act through PPARγ-dependent and -independent manners to protect 
Figure 7
Rosiglitazone-induced HO-1 expression via NOX/ROS-dependent c-Src/Pyk2/Akt pathway. HPAEpiCs were (A) transfected with p47 phox or NOX2
siRNA, and pretreated with APO or DPI, (B) c-Srci II, (C) PF431396 or (D) Akti VIII for 1 h, and then incubated with vehicle or rosiglitazone (30 μM) for the indicated time intervals. Western blot was performed by using an anti-phospho-c-Src, anti-c-Src, anti-phospho-Pyk2, anti-Pyk2, antiphospho-Akt or anti-Akt antibody. Data are expressed as mean ± SEM, from five independent experiments (n = 5). # P < 0.05, significantly different from rosiglitazone alone.
HO-1 attenuates LPS-induced ICAM-1 expression
against inflammatory responses (Chawla et al., 2001) . As shown in Figure 9A , pretreatment of HPAEpiCs with the PPARγ antagonist, GW9662, concentration-dependently inhibited the rosiglitazone-induced HO-1 protein and mRNA expression. These results were further confirmed by transfection with PPARγ siRNA, which markedly knocked down the level of PPARγ protein of either control or rosiglitazone treatment (control: 44 ± 7%; rosiglitazone: 51 ± 6%, si-PPARγ vs. Scrb) and also reduced the rosiglitazone-induced HO-1 expression by 33 ± 4% in HPAEpiCs ( Figure 9B ). Further, we observed that rosiglitazone time-dependently enhanced PPARγ promoter activity, which was inhibited by pretreatment with PPARγ antagonist GW9662 ( Figure 9C ). These results suggested the participation of PPARγ in the rosiglitazone-induced HO-1 expression in HPAEpiCs. HO-1 attenuates LPS-induced ICAM-1 expression et al., 2014) . Data in Figure 9D showed that both PPARγ antagonist (GW9662) and PPARγ siRNA markedly attenuated phosphorylation of PPARγ stimulated by rosiglitazone. Thus, whether rosiglitazone stimulated PPARγ phosphorylation via activation of NOX/ROS/c-Src/Pyk2/Akt/Nrf2 cascade was determined in HPAEpiCs. We found that transfection with p47 phox , NOX2, c-Src, Pyk2, Akt or Nrf2 siRNA had no significant effect on PPARγ phosphorylation stimulated by rosiglitazone ( Figure 9E ). Further, we also differentiated whether rosiglitazone-induced HO-1 expression was mediated through a PPARγ-dependent c-Src/Pyk2/Akt \cascade. We found that pretreatment with GW9662 or transfection with PPARγ siRNA failed to reduce the phosphorylation of c-Src, Pyk2 or Akt (Supporting Information Figure S1 ). These results suggested that rosiglitazone-induced HO-1 expression is mediated through either PPARγ-dependent or -independent manner in HPAEpiCs.
Discussion
Accumulating evidence indicates that rosiglitazone exerts anti-inflammatory effects through up-regulation of HO-1 in the pulmonary system (Liu et al., 2005; Kronke et al., 2007; Li et al., 2010; Xu et al., 2015b) , suggesting a possible therapeutic application for treatment of inflammatory diseases (Belvisi and Mitchell, 2009 ). In our previous study, we found that rosiglitazone suppressed LPS-induced nuclear translocation of phosphorylated NF-κB (p65) and expression of adhesion molecules through a PPARγ-dependent, up-regulation of HO-1 (Cho et al., 2018) . Here, we confirmed that rosiglitazone inhibited LPS-induced lung inflammation by inducing HO-1 independently of PPARγ. Further, application of pharmacological inhibitors and transfection with siRNAs inhibited rosiglitazone-induced HO-1 expression in HPAEpiCs. Our results demonstrated that HO-1 expression induced by rosiglitazone was mediated through activation of either a NOX/ROS/c-Src/Pyk2/Akt/Nrf2 pathway or a PPARγ cascade to suppress the inflammatory responses triggered by LPS (Figure 10 ). PPAR subtypes are expressed in many tissues (Kota et al., 2005) , and regulate several cellular functions (Michalik et al., 2006) . PPAR agonists such as WY-14643 (PPARα), GW501516 (PPARβ/δ) and rosiglitazone (PPARγ) induce HO-1 expression to inhibit inflammatory responses (Kronke et al., 2007; Sodhi et al., 2014) . Consistent with these findings, our results showed that agonitsts of these three subtypes of PPAR enhanced HO-1 expression in HPAEpiCs. Particularly, rosiglitazone possesses potential effects against acute lung injury and inflammation via HO-1 expression Lv et al., 2016) . Our results also confirmed that treatment of mice or HPAEpiCs with rosiglitazone significantly attenuated LPS-induced ICAM-1 expression and leukocyte adhesion, via up-regulation of HO-1.
ROS act as messengers in normal physiological functions or as inflammatory mediators, dependent on their concentration (Kamata and Hirata, 1999) . NOX/ROS-dependent HO-1 expression is induced by different stimuli (Srisook et al., 2006; Jamal Uddin et al., 2016) . Recently, an endogenous PPARγ ligand, 15d-PGJ 2 , induced ROS generation which promoted Nrf2-dependent expression of HO-1 (Koyani et al., 2016) . Therefore, NOX-dependent ROS generation may be involved in HO-1 up-regulation induced by rosiglitazone in HPAEpiCs. This was confirmed by the results that rosiglitazone-induced HO-1 expression was inhibited by NAC, APO and DPI. Moreover, NOX inhibitors prevent p47 phox phosphorylation or translocation to the membrane and thus inhibit NOX activation and ROS generation (Barbieri et al., 2004) . In line with these reports, our results demonstrated that pretreatment with APO or DPI attenuated rosiglitazone-induced NOX/ROS generation associated with HO-1 expression, suggesting that NOX/ROS play an important role in these responses. NOX/ROS-dependent HO-1 expression has been shown to be mediated through the activation of c-Src and Pyk2 (Han et al., 2009; Chi et al., 2015) and PI3K/Akt (Deng et al., 2013; Xu et al., 2015b) , which protects against oxidative injury. Our results confirmed that c-Src, Pyk2 and Akt are involved in HO-1 expression in HPAEpiCs, which may result from the phosphorylation of c-Src, Pyk2 and Akt stimulated by rosiglitazone. We also demonstrated that c-Src, Pyk2 and Akt are downstream targets of NOX/ROS, as rosiglitazonestimulated phosphorylation of c-Src was attenuated by NOX inhibitors or siRNA. The relationship among c-Src, Pyk2 and Akt in rosiglitazone-mediated responses was further differentiated by using the corresponding inhibitors. Pretreatment with c-Srci II inhibited the rosiglitazone-stimulated phosphorylation of c-Src and Pyk2, whereas PF43139 only attenuated phosphorylation of Pyk2, suggesting that Pyk2 is downstream of c-Src in rosiglitazone-mediated responses. We also observed that rosiglitazone-stimulated Akt phosphorylation was attenuated by PF431396 or Akti VIII, implying that Akt is downstream of c-Src/Pyk2. It is worth noting that phosphorylation of c-Src, Pyk2 and Akt was not changed by GW9662 or PPARγ siRNA. These results confirmed that rosiglitazone-induced HO-1 expression through a NOX/ROS-mediated c-Src/Pyk2/Akt phosphorylation is independent on PPARγ in HPAEpiCs.
Nrf2 controls the basal and inducible expression of an array of ARE-dependent genes to regulate the pathophysiological outcomes of oxidant exposure (Espinosa-Diez et al., 2015) . In our study, rosiglitazone mediated Nrf2 phosphorylation by promoting the degradation of Keap1 and nuclear accumulation of Nrf2 in HPAEpiCs. Phosphorylated Nrf2 translocation from the cytosol into the nucleus and binding to ARE were essential for HO-1 induction . Indeed, ChIP assay suggested that rosiglitazone increases Nrf2 interactions with ARE binding sites on the HO-1 promoter. Silencing Nrf2 expression by its siRNA attenuated HO-1 expression, but down-regulated Keap1 expression increased HO-1 protein levels in rosiglitazone-stimulated HPAEpiCs. These results are consistent with the reports that expression of HO-1, in response to up-regulated Nrf2 in post-transcriptional sites, protects cells from apoptosis in an Nrf2-denpendent manner (Foresti et al., 2013) . Moreover, the Akt/Nrf2 signalling pathway protects against toxicity (de Oliveira et al., 2015) . Here, we reported that blockade of the NOX/ROS/c-Src/Pyk2/Akt cascade by their respective inhibitors reduced rosiglitazonestimulated phosphorylation/nuclear translocation of Nrf2, HO-1 promoter binding and ARE promoter activity in HPAEpiCs. These results suggested that Nrf2 is an acceptor of these protein kinases in rosiglitazone-mediated responses.
On the other hand, PPARγ activation by rosiglitazone significantly increases HO-1 expression and attenuates airway inflammation and remodelling (Xu et al., 2015a) . In this study, blockade of PPARγ by its antagonist (GW9662) or siRNA, diminished rosiglitazone-mediated PPARγ phosphorylation and promoter activity in HPAEpiCs, suggesting the dependence of PPARγ on HO-1 expression. These results were consistent with the report indicating that PPARγ agonists block cigarette smoke extract-induced inflammatory responses through multiple PPARγ-mediated mechanisms (Lakshmi et al., 2014) . However, phosphorylation of PPARγ was independent on Nox/ROS/c-Src/Pyk2/Akt/Nrf2 cascade in rosiglitazone-stimulated HPAEpiCs. This was confirmed by transfection with respective siRNAs which had no significant effect on the rosiglitazone-stimulated phosphorylation of PPARγ. We also noted that both PPARγ-dependent and PPARγ-independent pathways are regulated by rosiglitazone. Our previous report indicated that rosiglitazone activated PPARγ binding to PPRE on HO-1 promoter to induce HO-1 transcription (Cho et al., 2018) . Moreover, in the present study, we focused on the Nrf2 activity in HO-1 induction. The studies of promoter activity indicated that PPARγ-PPRE (À1740 to À1881 bp) and Nrf2-ARE (À4019 to À4082 bp) response elements exhibited a similar trend in the transcriptional regulation (Kronke et al., 2007; Wang et al., 2013) . Our previous report also indicated that arachidonic acid increases HO-1 expression through the association of Nrf2 and PPARγ with ARE in rat astrocytes . Rosiglitazone shared the similar mechanism to induce the cooperation of PPARγ and Nrf2 on HO-1 expression.
In summary, these findings suggest that rosiglitazoneinduced HO-1 expression might play a protective role in lung inflammatory diseases, mediated via either NOX/ROSdependent c-Src/Pyk2/Akt activation of Nrf2 which binds to ARE regions or PPARγ. Although several detailed
Figure 10
A schematic pathway for rosiglitazone induced HO-1 expression in HPAEpiCs. Rosiglitazone attenuated LPS-induced ICAM-1 expression and lung monocyte/leukocyte accumulation by up-regulating HO-1 expression via two manners: PPARγ dependence and PPARγ independence. Activated PPARγ directly bound to PPARγ responsive element of HO-1 promoter, which increased the expression of HO-1 gene. In the PPARγ independent pathway, rosiglitazone enhanced NADPH oxidase activity, which resulted in the accumulation of intracellular ROS. Imbalance of oxidative stress promoted the phosphorylation of c-Src/Pyk2/Akt and the activation of Nrf2. After nuclear translocation, Nrf2 binds to the ARE region of HO-1 promoter and increases the expression of the HO-1 gene.
HO-1 attenuates LPS-induced ICAM-1 expression mechanisms should be elucidated in the future, these findings expand the application of PPARγ agonists as potential interventions for the prevention or treatment of pulmonary inflammatory diseases. Treatment with rosiglitazone at 2-4 weeks was associated with a modest improvement in pre-bronchodilator FEV 1 (forced expiratory volume in 1 s), peak expiratory flow and FEF (forced expiratory flow between 25 and 75% of the forced vital capacity) of asthmatic reaction (Spears et al., 2009; Richards et al., 2010) . Compared with rosiglitazone, administration of pioglitazone in mild asthma failed to improve any markers of airway inflammation, although it produced significant weight gains in asthmatic who were obese (Dixon et al., 2015; Anderson et al., 2016) . Rosiglitazone has been reported to be associated with an increased risk of congestive heart failure, acute myocardial infarction and mortality in the patients during treatment for Type 2 diabetes. However, they are still of research value because of their antiinflammatory activity in lung diseases (Home et al., 2007; Azimova et al., 2014) .
